PMID- 12898459 OWN - NLM STAT- MEDLINE DCOM- 20030925 LR - 20190725 IS - 0026-0495 (Print) IS - 0026-0495 (Linking) VI - 52 IP - 8 DP - 2003 Aug TI - Synergistic effects of testosterone and growth hormone on protein metabolism and body composition in prepubertal boys. PG - 964-9 AB - During human puberty there is a substantial increase in growth hormone (GH) and sex steroidal hormone concentrations, as well as in GH production rates and insulin-like growth factor-I (IGF-I) These studies were designed to investigate some of the interactions of testosterone (T) and GH in the metabolic changes of puberty. Ten boys with severe GH deficiency (GHD) were studied (mean age, 12.5 +/- 0.5 years) using stable isotope infusions, indirect calorimetry, and body composition analysis. After the baseline study, they received 2 doses of T enanthate (50 to 75 mg, intramuscular [IM]), and they were studied again 4 weeks later. The boys were then begun on daily subcutaneous (SC) GH (0.3 mg/kg/wk), while T therapy was continued for another 4 weeks and the studies repeated a third time. The treatment order was randomized. Protein oxidation rates decreased after T alone (-28%, P <.01), decreasing further after combined T/GH treatment (-36% v baseline, P <.01). The nonoxidative leucine disposal (NOLD), a measure of whole body protein synthesis, increased significantly after combined T/GH regardless of treatment order. The combination of T/GH also resulted in greater changes in body composition than T alone, with comparable decreases in %FM and corresponding increases in fat free mass (FFM). Measures of carbohydrate (CHO) metabolism, including glucose production and oxidation rates, were unaffected by either T or T/GH combination. Plasma IGF-I concentrations increased after T treatment and even more after T/GH combination, regardless of the treatment order. In conclusion GH and T are synergistic on whole body protein anabolism and body composition in males, even at a young age, but the positive effects of T on protein anabolism and body composition appear to need a basal amount of GH for those effects to be observed. GH and T both potentiate the development of the full body composition and metabolic changes of puberty. FAU - Mauras, Nelly AU - Mauras N AD - Nemours Children's Clinic Division of Endocrinology and Nemours Research Program, Jacksonville, FL 32207, USA. FAU - Rini, Annie AU - Rini A FAU - Welch, Susan AU - Welch S FAU - Sager, Brenda AU - Sager B FAU - Murphy, Suzanne P AU - Murphy SP LA - eng GR - R01DK51360/DK/NIDDK NIH HHS/United States GR - RR-00585/RR/NCRR NIH HHS/United States PT - Clinical Trial PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - United States TA - Metabolism JT - Metabolism: clinical and experimental JID - 0375267 RN - 0 (Growth Substances) RN - 0 (Hormones) RN - 0 (Keto Acids) RN - 0 (Proteins) RN - 3XMK78S47O (Testosterone) RN - 67763-96-6 (Insulin-Like Growth Factor I) RN - 816-66-0 (alpha-ketoisocaproic acid) RN - 9002-72-6 (Growth Hormone) RN - GMW67QNF9C (Leucine) RN - IY9XDZ35W2 (Glucose) SB - IM MH - Body Composition/*drug effects MH - Carbohydrate Metabolism MH - Child MH - Drug Synergism MH - Energy Metabolism/physiology MH - Glucose/metabolism MH - Growth Hormone/*pharmacology MH - Growth Substances/blood MH - Hormones/blood MH - Humans MH - Insulin-Like Growth Factor I/metabolism MH - Keto Acids/metabolism MH - Leucine/metabolism MH - Male MH - Oxidation-Reduction MH - Proteins/*metabolism MH - Sexual Maturation/physiology MH - Testosterone/*pharmacology EDAT- 2003/08/05 05:00 MHDA- 2003/09/26 05:00 CRDT- 2003/08/05 05:00 PHST- 2003/08/05 05:00 [pubmed] PHST- 2003/09/26 05:00 [medline] PHST- 2003/08/05 05:00 [entrez] AID - S002604950300163X [pii] AID - 10.1016/s0026-0495(03)00163-x [doi] PST - ppublish SO - Metabolism. 2003 Aug;52(8):964-9. doi: 10.1016/s0026-0495(03)00163-x.